Vistagen Therapeutics, Inc.
No SEC Form 4 filings for $VTGN in the last 30 days.
VistaGen Therapeutics has appointed Angel S. Angelov, M.D., MBA, as its new Chief Medical Officer, effective May 18, 2026. This appointment aims to bolster the company's efforts in advancing its neuropsychiatric and women's health programs, including pherine candidates in late-stage development. Angelov brings over two decades of clinical development experience from various pharmaceutical companies.
Vistagen Therapeutics, Inc. reported a material event in an 8-K filing, detailing the approval of retention awards in the form of stock option grants for all employees. Key executives, including the CEO, CLO, Chief Corporate Development Officer, COO, and CFO, each received options to purchase up to 75,000 shares of common stock. These options were granted on April 7, 2026, with an exercise price of $0.5358 per share, and will vest over two years in 25% increments every six months.
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Vistagen Therapeutics, Inc. (VTGN) concerning potential corporate wrongdoing by its officers and directors. The law firm is encouraging investors who purchased Vistagen securities before April 1, 2024, and still hold them, to contact them for more information and to assist in the investigation. The firm operates on a contingency fee basis, meaning there is no direct cost to investors unless they are successful in recovering funds.
